Kendra Harris, MD | LCMC Health

Dr. Kendra M. Harris

Claim this profile

Tulane University Health Sciences Center

Studies Prostate Cancer
Studies Cancer
11 reported clinical trials
35 drugs studied

Affiliated Hospitals

Image of trial facility.

Tulane University Health Sciences Center

Clinical Trials Kendra M. Harris is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

More about Kendra M. Harris

Clinical Trial Related

8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Kendra M. Harris has experience with

  • Biospecimen Collection
  • Atezolizumab
  • Apalutamide
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Data Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kendra M. Harris specialize in?

Is Kendra M. Harris currently recruiting for clinical trials?

Are there any treatments that Kendra M. Harris has studied deeply?

What is the best way to schedule an appointment with Kendra M. Harris?

What is the office address of Kendra M. Harris?

Is there any support for travel costs?